Primary ChAdOx1 vaccination fails to reactivate pre-existing, cross-reactive T cells

被引：0
|
作者：
Henze, L. [1 ,2 ,3 ,4 ,5 ]
Braun, J. [1 ,2 ,3 ,4 ,5 ]
Meyer-Arndt, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Juerchott, K. [1 ,2 ,3 ,4 ,5 ]
Schlotz, M. [9 ,10 ]
Michel, J. [12 ]
Grossegesse, M. [12 ]
Mangold, M. [1 ,2 ,3 ,4 ,5 ]
Dingeldey, M. [1 ,2 ,3 ,4 ,5 ]
Kruse, B. [1 ,2 ,3 ,4 ,5 ]
Holenya, P. [13 ]
Mages, N. [1 ,2 ,3 ,4 ,5 ]
Reimer, U. [13 ]
Eckey, M. [13 ]
Timmermann, B. [14 ]
Klein, F. [9 ,10 ,15 ,16 ]
Nitsche, A. [11 ,12 ]
Giesecke-Thiel, C. [14 ]
Loyal, L. [1 ,2 ,3 ,4 ,5 ]
Thiel, A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Tech Univ Berlin, Si M Simulierte Mensch Sci Framework, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Berlin Inst Hlth, Regenerat Immunol & Aging, BIH Immun, Berlin, Germany
[6] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany
[7] Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Neurol Expt Neurol, Berlin, Germany
[9] Univ Cologne, Expt Immunol Lab, Fac Med, Inst Virol, Cologne, Germany
[10] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[11] Robert Koch Inst, Highly Pathogen Viruses, Ctr Biol Threats & Special Pathogens, WHO Reference Lab SARS CoV, Berlin, Germany
[12] Robert Koch Inst, WHO Collaborating Ctr Emerging Infect & Biol Thre, Berlin, Germany
[13] JPT Peptide Technol GmbH, Berlin, Germany
[14] Max Planck Inst Mol Genet, Berlin, Germany
[15] German Ctr Infect Res DZIF, Partnersite Bonn Cologne, Cologne, Germany
[16] Univ Cologne, Ctr Mol Med Cologne CMMC, Cologne, Germany
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2023年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P69
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [1] Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
    Henze, Larissa
    Braun, Julian
    Meyer-Arndt, Lil
    Juerchott, Karsten
    Schlotz, Maike
    Michel, Janine
    Grossegesse, Marica
    Mangold, Maike
    Dingeldey, Manuela
    Kruse, Beate
    Holenya, Pavlo
    Mages, Norbert
    Reimer, Ulf
    Eckey, Maren
    Schnatbaum, Karsten
    Wenschuh, Holger
    Timmermann, Bernd
    Klein, Florian
    Nitsche, Andreas
    Giesecke-Thiel, Claudia
    Loyal, Lucie
    Thiel, Andreas
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains
    Nienen, Mikalai
    Stervbo, Ulrik
    Moelder, Felix
    Kaliszczyk, Sviatlana
    Kuchenbecker, Leon
    Gayova, Ludmila
    Schweiger, Brunhilde
    Juerchott, Karsten
    Hecht, Jochen
    Neumann, Avidan U.
    Rahmann, Sven
    Westhoff, Timm
    Reinke, Petra
    Thiel, Andreas
    Babel, Nina
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [3] Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
    Kim, Jinnam
    Kim, Changhyup
    Lee, Jung Ah
    Lee, Se Ju
    Lee, Ki Hyun
    Kim, Jung Ho
    Ahn, Jin Young
    Jeong, Su Jin
    Ku, Nam Su
    Yeom, Joon-Sup
    Song, Young Goo
    Choi, Jun Yong
    VACCINES, 2023, 11 (04)
  • [4] The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial
    Low, Jenny G.
    Wijaya, Limin
    Li, Greg K. Y.
    Lim, Eleanor Y. L.
    Shum, Aland K. L.
    Cheung, Yin-Bun
    Ooi, Eng-Eong
    TRIALS, 2015, 16
  • [5] The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial
    Jenny G Low
    Limin Wijaya
    Greg KY Li
    Eleanor YL Lim
    Aland KL Shum
    Yin-Bun Cheung
    Eng-Eong Ooi
    Trials, 16
  • [6] Cross-reactive and pre-existing antibodies to therapeutic antibodies-Effects on treatment and immunogenicity
    van Schie, Karin A.
    Wolbink, Gerrit-Jan
    Rispens, Theo
    MABS, 2015, 7 (04) : 662 - 671
  • [7] Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2
    Mveang Nzoghe, Amandine
    Essone, Paulin N.
    Leboueny, Marielle
    Maloupazoa Siawaya, Anicet Christel
    Bongho, Eliode Cyrien
    Mvoundza Ndjindji, Ofilia
    Avome Houechenou, Rotimi Myrabelle
    Agnandji, Selidji Todagbe
    Djoba Siawaya, Joel Fleury
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (01) : 128 - 133
  • [8] The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
    Murray, Sam M. M.
    Ansari, Azim M. M.
    Frater, John
    Klenerman, Paul
    Dunachie, Susanna
    Barnes, Eleanor
    Ogbe, Ane
    NATURE REVIEWS IMMUNOLOGY, 2023, 23 (05) : 304 - 316
  • [9] The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
    Sam M. Murray
    Azim M. Ansari
    John Frater
    Paul Klenerman
    Susanna Dunachie
    Eleanor Barnes
    Ane Ogbe
    Nature Reviews Immunology, 2023, 23 : 304 - 316
  • [10] Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia
    Balingit, Jean Claude
    Denis, Dionisius
    Suzuki, Ryosuke
    Hayati, Rahma Fitri
    Tun, Mya Myat Ngwe
    Takamatsu, Yuki
    Masyeni, Sri
    Sasmono, R. Tedjo
    Morita, Kouichi
    VIRUS RESEARCH, 2024, 348
12345